Forte Biosciences Q1 net loss $1.37/share; FB102 celiac data expected, vitiligo trial dosed

Forte Biosciences, Inc.

2025-Q1 EPS reported -$1.37

Net loss per share ($1.37) vs ($4.03) YoY; net loss $15.7M on R&D spend of $12.7M.
Cash $45.9M at March 31, 2025, up from $22.2M at year-end 2024.
FB102 celiac disease topline data planned for Q2 2025; first vitiligo patient dosed.
R&D expenses $12.7M (+188% YoY) driven by manufacturing and clinical trial costs.
Shares outstanding 6.6M plus 4.8M pre-funded warrants as of March 31, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.